Annual Meeting

Targeting nitrated proteins could lead to new cancer drugs

Núria  Negrão
April 30, 2021

Glioblastoma multiforme is a type of cancer that develops in the brain. Aggressive and difficult to treat, glioblastoma tumors respond to few drugs, and most patients are treated with methods developed about 20 years ago. Kyle Nguyen, a second-year Ph.D. student in Maria Franco’s laboratory at Oregon State University, has been looking for a new way to target these tumors. He will present his work on Friday, 3–3:15 p.m. EDT, at the 2021 ASBMB Annual Meeting.

Courtesy of Kyle Nguyen
Kyle Nguyen in one of the Franco lab’s tissue culture rooms.

In broad terms, the Franco lab is interested in the role of oxidative stress in diseases of the nervous system. Oxidative stress is a chemical imbalance inside cells that leads to an accumulation of oxidants that damage healthy cells. It has been linked to aging and various diseases, including cancer. The lab studies the role of oxidants in the development and growth of tumors of the nervous system.

Franco lab
A confocal microscope image of actin polymerization within glioblastoma cells. Actin is in red, cell nuclei are in blue.

Peroxynitrite is the most powerful oxidant produced in cancer cells and in cells associated with other diseases. When peroxynitrite reacts with proteins it causes oxidative changes that can negatively affect the way the proteins work in the cells. “As far as we know, these are permanent chemical changes,” Nguyen said.

The lab is interested in tyrosine nitration, one of the changes mediated by peroxynitrite. Tyrosine nitration is virtually undetectable in normal tissues, Nguyen explained, so drugs that target nitrated proteins would not affect healthy cells. His project looked at tyrosine nitration of a protein called heat shock protein 90, or Hsp90. Nitrated Hsp90 promotes the survival of tumor cells, and this role is mediated by nitration of tyrosine residues within this protein.

In his work, Nguyen shows that tyrosine nitration supports the survival and migration of glioblastoma cells and thus is important for tumor development, and that nitrated Hsp90 may play more than one role in these tumors. Non-tumor cells do not have nitrated Hsp90 and tumor cells do, so targeting nitrated Hsp90 or other nitrated proteins could selectively kill tumor cells with few side effects.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Núria  Negrão

Núria Negrão is a medical writer and editor at Cactus Communications.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Differences in pili structure modulate bacterial behavior
Journal News

Differences in pili structure modulate bacterial behavior

April 14, 2026

Researchers demonstrate how small changes in the structure of hair-like protein appendages can affect the behavior of Acinetobacter bacteria.

Cholesterol regulatory genes predict liver transplant outcomes
Journal News

Cholesterol regulatory genes predict liver transplant outcomes

April 10, 2026

Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.

Lipid signatures for a rare neurological disorder
Journal News

Lipid signatures for a rare neurological disorder

April 10, 2026

Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.

Disease-linked mutations disrupt protein phase behavior
Journal News

Disease-linked mutations disrupt protein phase behavior

April 9, 2026

Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Journal News

The dual role of asprosin in chronic fatty liver disease

April 8, 2026

Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Journal News

Novel inhibitor targets RAS-driven cancers

April 7, 2026

Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.